Skip to main content Help with accessibility Skip to main navigation

RIVAROXABAN 2.5mg tablets (Xarelto®▼) for the prevention of atherothrombotic events

CCG Approval Status:

Date Added: 28 - Nov - 2019
Body System:
Green

The Pan Mersey Area Prescribing Committee recommends the prescribing of RIVAROXABAN 2.5mg tablets (Xarelto®▼) plus aspirin, for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events, in accordance with NICE TA607.